Neuromyelitis optica spectrum disorder differential diagnosis

Neuromyelitis optica spectrum disorder Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Neuromyelitis optica spectrum disorder from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Radiation therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Neuromyelitis optica spectrum disorder differential diagnosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Neuromyelitis optica spectrum disorder differential diagnosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Neuromyelitis optica spectrum disorder differential diagnosis
CDC on Neuromyelitis optica spectrum disorder differential diagnosis
Neuromyelitis optica spectrum disorder differential diagnosis in the news
Blogs on Neuromyelitis optica spectrum disorder differential diagnosis
Directions to Hospitals Treating Neuromyelitis optica spectrum disorder
Risk calculators and risk factors for Neuromyelitis optica spectrum disorder differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes

Overview

• Neuromyelitis optica spectrum disorder (NMOSD) must be differentiated from other disorders that can cause optic neuritis, acute myelitis, longitudinally extensive transverse myelitis, area postrema syndrome, brainstem syndromes, or inflammatory-appearing lesions of the brain and spinal cord.
• The most important inflammatory differential diagnoses are myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS). Other important mimics include neurosarcoidosis, systemic autoimmune or vasculitic disease, infectious myelitis, paraneoplastic and neoplastic disorders, vascular myelopathy, metabolic disease, and compressive myelopathy.
• Differentiation requires correlation of the clinical syndrome and attack tempo with serum aquaporin-4 immunoglobulin G (AQP4-IgG), serum myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG), magnetic resonance imaging (MRI), and—when clinically appropriate—cerebrospinal fluid (CSF) and targeted studies for competing diagnoses. AQP4-IgG and MOG-IgG should be tested using appropriate cell-based assays (CBAs). Current Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) consensus recommendations support syndrome-directed MRI assessment.
• No single clinical or MRI feature is pathognomonic. A red flag should trigger a deliberate search for an alternative diagnosis but does not, by itself, absolutely exclude NMOSD.

Differentiating Neuromyelitis optica spectrum disorder from other diseases

Major inflammatory and demyelinating mimics

• Neuromyelitis optica spectrum disorder must first be distinguished from MOGAD and MS, followed by other inflammatory, infectious, autoimmune, and paraneoplastic mimics according to the presenting syndrome.

Major inflammatory disorders that may mimic NMOSD

Differential diagnosis	Overlapping features	Findings that favor the alternative diagnosis
MOGAD	Optic neuritis, acute myelitis including longitudinally extensive transverse myelitis (LETM), brainstem disease, and cerebral attacks may resemble NMOSD.	A compatible clinical phenotype with serum MOG-IgG detected by an appropriate CBA favors MOGAD. Supportive clues include anterior optic-nerve involvement, optic-disc swelling, perineural optic-nerve-sheath enhancement, conus involvement, an axial spinal-cord H-sign, acute disseminated encephalomyelitis-like lesions, cortical encephalitis with seizures, and more complete resolution of MRI lesions. An AQP4-IgG-negative patient who fulfills the international MOGAD criteria should be classified as MOGAD rather than NMOSD.
Multiple sclerosis (MS)	Optic neuritis, myelitis, brainstem syndromes, and white-matter lesions may overlap with NMOSD.	MS is favored by relapse-independent chronic progression; short, sharply demarcated, predominantly peripheral spinal-cord lesions; ovoid periventricular lesions perpendicular to the ventricles (Dawson fingers); inferior temporal, cortical, or juxtacortical U-fiber lesions; persistent CSF-restricted oligoclonal bands; and accumulation of clinically silent MRI lesions. Suspected MS should be assessed independently under the current McDonald diagnostic criteria and only after better explanations, including NMOSD and MOGAD, have been excluded.
Acute disseminated encephalomyelitis	Multifocal central nervous system inflammation may include optic neuritis, myelitis, brainstem dysfunction, and large cerebral lesions.	Encephalopathy accompanying a polyfocal demyelinating event, particularly in a child, and large bilateral poorly demarcated MRI lesions favor acute disseminated encephalomyelitis. Because this phenotype is common in MOGAD, serum MOG-IgG testing should be considered when the clinical and imaging features are compatible.
Neurosarcoidosis	Optic neuropathy, LETM, brainstem disease, and hypothalamic or meningeal involvement may resemble NMOSD.	A progressive course, fever, night sweats, mediastinal or hilar lymphadenopathy, leptomeningeal or nerve-root enhancement, dorsal subpial spinal enhancement, or the axial spinal-cord “trident sign” favors neurosarcoidosis. Tissue demonstration of noncaseating granulomatous inflammation, after excluding alternative granulomatous causes, provides the strongest diagnostic support.
Systemic autoimmune or vasculitic disease	Systemic lupus erythematosus, Sjögren syndrome, Behçet disease, antiphospholipid syndrome, and systemic or primary central nervous system vasculitis may be associated with optic, spinal-cord, cerebral, or vascular syndromes.	Systemic manifestations, disease-specific serology, vascular-territory lesions, meningeal disease, or biopsy findings may support the alternative diagnosis. However, connective-tissue and other autoimmune disorders can coexist with AQP4-IgG-positive NMOSD; their presence alone must not be used to reject NMOSD.
Autoimmune glial fibrillary acidic protein astrocytopathy	Meningoencephalomyelitis, brainstem symptoms, and longitudinal spinal-cord lesions may resemble NMOSD.	A meningoencephalitic presentation and linear radial perivascular gadolinium enhancement are important clues. In an appropriate phenotype, CSF glial fibrillary acidic protein immunoglobulin G supports this diagnosis.
Paraneoplastic neurologic disease	Optic neuropathy, myelopathy, brainstem disease, or diencephalic syndromes can overlap with NMOSD.	A known cancer, constitutional symptoms, an atypical progressive or multifocal syndrome, suspicious imaging, or a phenotype-specific neural antibody supports a paraneoplastic disorder. AQP4-IgG positivity does not absolutely exclude rare paraneoplastic NMOSD; cancer evaluation should be targeted to clinical risk factors and findings rather than performed invasively in every patient.
Infectious myelitis or meningoencephalomyelitis	Viral, bacterial, spirochetal, and mycobacterial infections may cause optic, spinal-cord, brainstem, or cerebral inflammation.	Fever, meningism, immunocompromise, exposure history, marked or atypical CSF inflammation, low CSF glucose, or pathogen-specific testing may indicate infection. Important considerations include varicella-zoster virus, herpes simplex virus, cytomegalovirus, enteroviruses, human immunodeficiency virus, human T-lymphotropic virus types 1 and 2, West Nile virus, tuberculosis, syphilis, Lyme neuroborreliosis, and Bartonella henselae. A recent infection can also precede a genuine NMOSD attack, so temporal association alone is not diagnostic.

Table adapted and clinically summarized from the 2015 International Panel for Neuromyelitis Optica Diagnosis consensus criteria, the 2023 Neuromyelitis Optica Study Group recommendations, the 2023 International MOGAD Panel criteria, and Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) consensus recommendations.

Urgent structural, vascular, neoplastic, and metabolic mimics

• Neuromyelitis optica spectrum disorder should not be diagnosed until urgent structural, vascular, neoplastic, and other non-inflammatory explanations appropriate to the clinical syndrome have been excluded.

Non-inflammatory disorders that require active exclusion

Differential diagnosis	Overlapping features	Findings that favor the alternative diagnosis
Compressive myelopathy	Weakness, a sensory level, sphincter dysfunction, and cord signal abnormality may resemble acute myelitis.	Mechanical or radicular pain, vertebral or disc disease, an epidural process, and direct cord compression on urgent spinal MRI favor a structural cause. Compression must be excluded before an inflammatory myelopathy is diagnosed.
Spinal cord infarction	Acute motor, sensory, and autonomic dysfunction may resemble an NMOSD myelitis attack.	A hyperacute deficit reaching its nadir in less than 4 hours, a vascular trigger or risk factor, and a vascular-territory or diffusion-restricted lesion favor infarction. A hyperacute attack tempo is a consensus red flag against NMOSD.
Spinal dural arteriovenous fistula	A longitudinal spinal-cord lesion, lower-limb weakness, sensory symptoms, and bladder dysfunction may mimic inflammatory myelitis.	A chronic progressive or fluctuating myelopathy, lower thoracic or conus-predominant edema, and serpiginous perimedullary vessels or flow voids favor a spinal dural arteriovenous fistula. Spinal vascular imaging and catheter angiography are used when suspicion persists.
Central nervous system lymphoma or intramedullary spinal-cord tumor	Cord enlargement, enhancement, and longitudinal lesions can resemble NMOSD.	Continual worsening for more than 4 weeks, a focal mass, disproportionate cord expansion, persistent gadolinium enhancement for more than 3 months, or enhancement despite immunotherapy favors neoplasm or another non-NMOSD process. When feasible, serum AQP4-IgG and MOG-IgG should be assessed and inflammatory mimics carefully excluded before spinal-cord biopsy is pursued.
Metabolic, nutritional, or genetic disease	Optic neuropathy or a subacute myelopathy may resemble an NMOSD core syndrome.	Symmetric tract-predominant disease, a non-attack-like course, relevant laboratory abnormalities, family history, or a characteristic genetic result favors vitamin B12, folate, vitamin E, copper, or biotinidase deficiency; Leber hereditary optic neuropathy; or a leukodystrophy.

Syndrome-directed distinctions

• Neuromyelitis optica spectrum disorder should be differentiated using the clinical and imaging pattern of the presenting core syndrome rather than any isolated finding.

Clinical and imaging clues by presenting syndrome

Presenting syndrome	Findings that support NMOSD	Findings that should redirect the differential diagnosis
Optic neuritis	Severe visual loss, posterior optic-nerve or chiasmal involvement, or a lesion extending through at least half the optic nerve is characteristic, although not specific.	Anterior optic-nerve disease, marked disc swelling, or perineural enhancement favors MOGAD; a short retrobulbar lesion favors MS; sudden painless altitudinal loss favors ischemic optic neuropathy; and steadily progressive loss suggests compressive, infiltrative, toxic, nutritional, or hereditary optic neuropathy.
Acute myelitis	A central LETM lesion, cord swelling, bright spotty lesions, patchy enhancement, cavitation in severe attacks, or extension from the upper cervical cord into the medulla supports NMOSD.	Conus involvement or an H-sign favors MOGAD; short, peripheral, sharply demarcated lesions favor MS; hyperacute onset favors infarction; root, leptomeningeal, dorsal subpial, or trident-sign enhancement suggests neurosarcoidosis; persistent enhancement or a progressive course suggests neoplasm or vascular malformation.
Area postrema syndrome	Otherwise unexplained hiccups, nausea, or vomiting lasting at least 48 hours, particularly with a dorsal medullary lesion, supports an NMOSD core syndrome.	Absence of a compatible dorsal medullary lesion does not exclude NMOSD, but gastrointestinal, metabolic, toxic, medication-related, vestibular, infectious, and structural posterior-fossa causes should be assessed when the history or examination suggests them.
Brainstem, diencephalic, or cerebral syndrome	Dorsal medullary, periependymal, hypothalamic, long corticospinal-tract, extensive corpus-callosum, or large confluent white-matter lesions can support NMOSD in the appropriate clinical context.	A pontine or middle-cerebellar-peduncle predominance, deep-gray involvement, acute disseminated encephalomyelitis-like lesions, cortical encephalitis, seizures, or leptomeningeal enhancement favors MOGAD; classic MS lesion topography favors MS; radial perivascular enhancement suggests glial fibrillary acidic protein astrocytopathy or another inflammatory/infiltrative disorder.

Consensus red flags requiring diagnostic reassessment

• Neuromyelitis optica spectrum disorder should be reassessed whenever one or more of the following consensus red flags are present.
• Neuromyelitis optica spectrum disorder should be reconsidered when neurologic decline is steadily progressive and independent of discrete attacks.
• A time to attack nadir of less than 4 hours suggests ischemia or infarction; continual worsening for more than 4 weeks suggests neurosarcoidosis, neoplasm, or another alternative process.
• Persistent CSF-restricted oligoclonal bands or a positive measles-rubella-zoster virus antibody reaction favor MS, although oligoclonal bands can occur in a minority of patients with NMOSD.
• MRI red flags include classic MS-pattern brain lesions; predominantly peripheral short spinal-cord lesions; gadolinium enhancement persisting for more than 3 months or despite immunotherapy; linear radial perivascular enhancement; a focal mass; or vascular-flow abnormalities.
• Established or suspected sarcoidosis, malignancy, or chronic infection requires targeted evaluation. These conditions may occasionally coexist with NMOSD, so the final diagnosis must integrate all clinical, serologic, CSF, imaging, and—when necessary—pathologic evidence.
• Isolated CSF AQP4-IgG positivity with negative serum testing, AQP4 immunoglobulin M or immunoglobulin A without AQP4-IgG, an unexpected low-positive result, or apparent AQP4-IgG/MOG-IgG double positivity should prompt repeat serum testing with an appropriate alternative CBA and expert review.

Practical differential-diagnosis sequence

• Neuromyelitis optica spectrum disorder should be differentiated from competing diagnoses in the following sequence.

1. Confirm that the presentation represents an acute NMOSD-compatible core syndrome and establish the time from symptom onset to nadir.
2. Obtain syndrome-directed MRI: brain and complete spinal cord in all suspected cases, dedicated orbital imaging for optic neuritis when required, and gadolinium-enhanced imaging when not contraindicated. Diffusion- and susceptibility-sensitive sequences can help identify vascular and neoplastic mimics.
3. Test serum AQP4-IgG and, when indicated, serum MOG-IgG using appropriate CBAs. Confirm unexpected, low-positive, or double-positive results, particularly when clinical or imaging red flags are present.
4. Perform CSF analysis when clinically appropriate to distinguish NMOSD from MS, infection, malignancy, and other inflammatory disorders. Core studies include cell count and differential, erythrocyte count, protein, glucose, lactate, and CSF-restricted oligoclonal bands; add microbiology, cytology, flow cytometry, or other tests according to the suspected mimic.
5. Order targeted systemic studies according to the phenotype and red flags—for example, infectious testing, autoimmune serology, chest imaging or tissue biopsy for suspected sarcoidosis, cancer evaluation, metabolic studies, or spinal vascular imaging. Broad invasive cancer screening is not routinely recommended without clinical indications.
6. Apply the 2015 International Panel for Neuromyelitis Optica Diagnosis criteria only after a better alternative diagnosis has been excluded. If an AQP4-IgG-negative patient fulfills the international MOGAD criteria, classify the disease as MOGAD rather than NMOSD.